Taivex Therapeutics Corporation
Taivex Therapeutics Corporation focuses on developing oncology drugs with a commitment to responsible and ethical practices, sustainable development, and respecting individual, societal, and environmental needs. The company aims to overcome unmet medical needs in cancer treatment through innovative therapies and has a strong pipeline of targeted cancer drugs, including T-1101, T-1201, and T-1301. With a history of milestones such as FDA and TFDA approvals, clinical trial progress, and awards for innovation, Taivex is dedicated to advancing cancer therapeutics and improving patient outcomes worldwide.
Industries
Nr. of Employees
small (1-50)
Taivex Therapeutics Corporation
2F., No. 12, Dongxing Rd., Songshan Dist., Taipei City 105, Taiwan (R.O.C.)
Products
T-1101
A first-in-class oral small-molecule inhibitor that disrupts Hec1–Nek2 interaction; advanced through preclinical studies and early-phase clinical trials with oral powder and capsule formulations.
T-1201
A targeted small-molecule drug conjugate that binds a tumor-associated surface marker to deliver an SN-38 cytotoxic payload; demonstrated preclinical efficacy in multiple xenograft models and evaluated in Phase I clinical studies.
T-1301
A multi-targeted small-molecule tyrosine kinase inhibitor developed to inhibit multiple kinases including clinically relevant mutants, with preclinical activity in hematologic and solid tumor models and progression through Phase I clinical testing.
T-1101
A first-in-class oral small-molecule inhibitor that disrupts Hec1–Nek2 interaction; advanced through preclinical studies and early-phase clinical trials with oral powder and capsule formulations.
T-1201
A targeted small-molecule drug conjugate that binds a tumor-associated surface marker to deliver an SN-38 cytotoxic payload; demonstrated preclinical efficacy in multiple xenograft models and evaluated in Phase I clinical studies.
T-1301
A multi-targeted small-molecule tyrosine kinase inhibitor developed to inhibit multiple kinases including clinically relevant mutants, with preclinical activity in hematologic and solid tumor models and progression through Phase I clinical testing.
Services
Design and execution support for Phase I and Phase II oncology trials including dose escalation, PK and safety evaluation, and multicenter coordination.
Lead discovery, target-directed compound development, in vitro assays and in vivo efficacy testing in xenograft models to support IND-enabling activities.
Transfer of compound technologies and collaborative development with public research institutes and contract partners to advance candidates from research to development.
Preparation and filing of patents covering compounds, methods, biomarkers and formulations across multiple jurisdictions.
Design and execution support for Phase I and Phase II oncology trials including dose escalation, PK and safety evaluation, and multicenter coordination.
Lead discovery, target-directed compound development, in vitro assays and in vivo efficacy testing in xenograft models to support IND-enabling activities.
Transfer of compound technologies and collaborative development with public research institutes and contract partners to advance candidates from research to development.
Preparation and filing of patents covering compounds, methods, biomarkers and formulations across multiple jurisdictions.
Expertise Areas
- Oncology drug discovery
- Small-molecule therapeutics
- Small-molecule drug conjugates (SMDC)
- Tyrosine kinase inhibitor development
Key Technologies
- Small-molecule inhibitor discovery
- Small-molecule drug conjugates (SMDC)
- Multi-targeted tyrosine kinase inhibition
- Biomarker-targeted delivery (phosphatidylserine targeting)
News & Updates
Taivex announced that its investigational drug T-1101 has received approval from Taiwan’s Food and Drug Administration (TFDA) to initiate Phase II clinical trials, further evaluating safety and efficacy in patients with neuroendocrine tumors.
Taivex will present the T-1201 Phase I clinical trial design at the 2025 ASCO Annual Meeting, highlighting its progress and potential impact.
Taivex announced FDA approval for T-1101 to proceed to Phase II trials, focusing on neuroendocrine tumors.
Latest clinical trial data for T-1101 accepted for publication at ASCO 2025, emphasizing its innovation and clinical relevance.
Taivex, in collaboration with the Development Center for Biotechnology, developed T-1101, a first-in-class Hec1/Nek2 inhibitor, which received the MOEA 2011 Breakthrough Innovation of the Year Award.
T-1201, developed with the Institute of Biotechnology and Pharmaceutical Research at NHRI, received the 2017 Taipei Biotech Award Gold Medal for its innovative anti-tumor drug delivery system.
Taivex announced that its investigational drug T-1101 has received approval from Taiwan’s Food and Drug Administration (TFDA) to initiate Phase II clinical trials, further evaluating safety and efficacy in patients with neuroendocrine tumors.
Taivex will present the T-1201 Phase I clinical trial design at the 2025 ASCO Annual Meeting, highlighting its progress and potential impact.
Taivex announced FDA approval for T-1101 to proceed to Phase II trials, focusing on neuroendocrine tumors.
Latest clinical trial data for T-1101 accepted for publication at ASCO 2025, emphasizing its innovation and clinical relevance.
Taivex, in collaboration with the Development Center for Biotechnology, developed T-1101, a first-in-class Hec1/Nek2 inhibitor, which received the MOEA 2011 Breakthrough Innovation of the Year Award.
T-1201, developed with the Institute of Biotechnology and Pharmaceutical Research at NHRI, received the 2017 Taipei Biotech Award Gold Medal for its innovative anti-tumor drug delivery system.